DEALS
最新交易
中倫代表再鼎醫(yī)藥在納斯達克上市
2017年9月22日，再鼎醫(yī)藥有限公司（股票代碼：ZLAB）宣布完成首次公開發(fā)行美國存托股份并在納斯達克全球市場上市；在承銷商完全行使超額配售權(quán)后，本次發(fā)行募資總額約1.725億美元。摩根大通、花旗集團和Leerink Partners擔(dān)任本次發(fā)行的聯(lián)席賬簿管理人。
?
再鼎醫(yī)藥是一家總部位于上海的創(chuàng)新生物醫(yī)藥公司，致力于專有療法的發(fā)現(xiàn)或許可、開發(fā)和商業(yè)化應(yīng)用，以解決包括腫瘤、自身免疫、傳染性疾病等在內(nèi)領(lǐng)域的中國市場上大量未滿足的醫(yī)療需求。
?
中倫律師事務(wù)所在本次發(fā)行中擔(dān)任發(fā)行人再鼎醫(yī)藥的中國法律顧問。中倫律師團隊由合伙人趙靖、賈海波和程芳負(fù)責(zé)，還包括律師鄭澤坤、張琳竺和章舒熳等。
?
On September 22, 2017, Zai Lab Limited?(Nasdaq: ZLAB) announced the closing of its initial public offering of American depositary shares, which have been listed on the Nasdaq Global Market, raising gross proceeds of approximately US$172.5 million upon the underwriters’ full exercise of the over-allotment option.? J.P. Morgan,?Citigroup?and?Leerink Partners?acted as joint book-running managers for the offering.
?
Zai Lab is an innovative biopharmaceutical company based in Shanghai focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the areas of oncology, autoimmune and infectious diseases.?
?
Zhong Lun Law Firm acted as Zai Lab’s PRC legal counsel in the offering. The legal team from Zhong Lun was led by Anthony Zhao, William Jia and Helen Cheng,?and included Roy Zheng, Lindsay Zhang and Shuman Zhang, etc.
?
